Hepatology

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2770
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	2366
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	2122
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1569
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	547
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	351
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	342
Late-Breaking Abstracts	295
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	261
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	244
Cover Image	208
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	203
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	201
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	190
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	178
Reply	154
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	149
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	146
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	143
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	143
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	140
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?	133
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	131
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	124
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	124

Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus	123
Regulatory role and translational potential of CCL11 in liver fibrosis	121
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	119
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	117
Efficacy and safety of infliximab in patients with autoimmune hepatitis	115
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium	114
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	110
Access to technology to support telehealth in areas without specialty care for liver disease	107
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	106
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	106
Low-dose chemotherapy remodels hepatic immune landscape and potentiates antitumor response to immune checkpoint blockade in cholangiocarcinoma	103
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	102
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	101
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	101
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	101
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	99
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	97
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	97
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	96
	95
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	92
Genes that fit just right: Unzipping the genome of fatty liver disease	91
In vivo imaging of calcium dynamics in zebrafish hepatocytes	90
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	90
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	88
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	86
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	85
Reply	82
Retraction: Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma	81
Reply: The CRAPT-M score: Robust enough for clinical practice?	81
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	80
The digital determinants of liver disease	79
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	79
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	78
Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency	78
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	77
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	76
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	75
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	75
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	75
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	75
Letter to the Editor: Overlooking the important factor: Hypoxia	74
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	73
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	73
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	69
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	69
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	68
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	68
The international quest for the imaging diagnosis of liver cancer	66
Much more needed in natural history of Alagille syndrome	65

National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	63
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD	63
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	63
Metabolic dysfunction-associated steatotic liver disease and the heart	62
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	62
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells	61
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	61
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	61
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA	61
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	60
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	59
Reply: Deep learning and digital pathology power prediction of HCC development in steatotic liver disease	58
Reply: Diabetes and fibrosis—Parallel risks or overlap?	57
Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence	57
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	57
On-treatment LSM: A crystal ball for chronic hepatitis B outcomes	57
Therapeutic manipulation of the microbiome in liver disease	57
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis	57
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	56
NAFLD‐related hepatocellular carcinoma: The growing challenge	56
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	55
Immunobiology of primary sclerosing cholangitis	55
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	55
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	54
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	54
The clot and the complicated consult	54
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	53
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	53
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	52
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	52
Myeloid CD36 deficiency alleviates hepatic fibrosis by promoting adaptive immunity of macrophages	52
Manuscript best practices: Takeaways from a community conversation	52
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	52
Reply	51
Reply	51
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	50
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	50
Reply	50
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	50
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	50
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	49
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	49
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	49
Hepatology Highlights	49
A bright future: Sustainable treatment of gastric varices	48
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	47
Letter to the Editor: Placebo drift, dose heterogeneity, and the winner’s curse—Re-evaluating the hierarchy of MASH therapeutics	47
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	47
Integrative Hepatology: Enhancing overall health to manage liver disease	46
Pathway to global elimination of hepatitis B: HBV cure is just the first step	46
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	46
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	46
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	45
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	45
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	45
Reply	45
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	45
Glutamine synthetase loss in β-catenin–mutant hepatocellular carcinoma promotes tumor burden through macrophage metabolic reprogramming	45
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	45
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	44
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	44
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	44
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	44
Natural history and development of a novel composite endpoint in patients with alcohol-associated hepatitis: Data from a prospective multicenter study	44
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	44
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	43
AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation	43
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	43
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	42
Future directions in acute liver failure	42
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	42
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	42
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	42
Masthead	42
Predicting liver outcomes with biomarker monitoring in MASLD	42
Reply: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	42
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	42
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	42
Letter to the editor: HuR in liver homeostasis	41
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	41

Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	41
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	41
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	41
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	41
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	40
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	39
Lipid nanoparticle-delivered ornithine transcarbamylase mRNA alleviates liver fibrosis in preclinical models	39
Letter to the Editor: The profile of HBsAg levels after nucleos(t)ide analogues treatment is crucial for achieving a functional cure	39
The Liver Meeting: 2025 Abstracts	39
Intrahepatic cholangiocarcinoma PANoptosidy	38
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	38
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	38
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	38
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	37
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	37
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	37
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	37
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	37
Anatomic subsets of cholangiocarcinoma: More different than alike	37
Telehealth interventions in patients with chronic liver diseases: A systematic review	37
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	37
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	37
Letter to the Editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	37
Erratum: Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	36
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	36
Imaging for better responses to immunotherapy in hepatocellular carcinoma	36
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	36
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	36
Erratum: Single-cell immune profiling of mouse liver aging reveals Cxcl2+ macrophages recruit neutrophils to aggravate liver injury	36
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	36
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	36
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	35
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	35
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial	35
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	35
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	34
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	34
The evolving role of liver sinusoidal endothelial cells in liver health and disease	34
Prognostic significance of mild ascites in patients with cirrhosis	34
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	34
Stroma-driven intertumoral and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation	34
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	34
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	33
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	33
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	33
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	33
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	33
A global action agenda for turning the tide on fatty liver disease	33
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	33
Category Index	32
Category Index	32
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	32
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	32
Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 axis in CTNNB1-mutant hepatocellular carcinoma	32
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	32
Letter to the Editor: Assessing HCC risk in HBV indeterminate phase	32
Erratum: A prognostic strategy based on stage of cirrhosis and HVPG to improve risk stratification after variceal bleeding	31
Reply: More on nonalcoholic/nonmetabolic dysfunction–associated steatohepatitis	31
The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome	31
Abdominal surgery in patients with chronic noncirrhotic extrahepatic portal vein obstruction: A multicenter retrospective study	31
Retraction: Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective	31
Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing liver transplantation survival benefit	31
LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism	31
Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi	31
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries	31
Deep learning’s crystal ball: Predicting HCC surgery success with multimodal imaging	31
MASLD: To screen or not to screen—That is the question	31
Population-level screening for liver disease: Opportunities and challenges	31
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma	30
Letter to the editor: Hepatitis B virus reactivation in immune checkpoint inhibitor‐based combination therapies for hepatocellular carcinoma	30
Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B	30
Age and the relative importance of liver‐related deaths in nonalcoholic fatty liver disease	30
Response evaluation to systemic therapy in HCC: Current challenges and future perspectives	30
Letter to the Editor: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC	30
Letter to the Editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	30
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone	30
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series	30
Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	30
Erratum: Late breaking abstracts	30
AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension	30
Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline	30
Unmet needs in diagnosis and management of portopulmonary hypertension: How far have we reached?	29
Process Measures to Improve Outcomes During Peri-Procedure Management of Coagulopathy in Cirrhosis	29
Hepatitis D virus—still the devil!	29
Benefit and harm of waiting time in liver transplantation for HCC	29
CAD manipulates tumor intrinsic DHO/UBE4B/NF-κB pathway and fuels macrophage cross-talk, promoting HCC metastasis	29
Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET–activated and β-catenin–mutated hepatocellular carcinoma	29
Epigenetic heterogeneity hotspots in human liver disease progression	29
Will noninvasive screening for fibrosis/steatosis open Pandora’s box? Sharing the healthcare burden of state-of-the-art hepatology practice	29
Video introduction: Special issue on alcohol use disorder and liver disease	28
Erratum: KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration	28